105 related articles for article (PubMed ID: 10818440)
1. Pharmacological characterization of phospholipid growth-factor receptors.
Tigyi G; Fischer DJ; Baker D; Wang DA; Yue J; Nusser N; Virag T; Zsiros V; Liliom K; Miller D; Parrill A
Ann N Y Acad Sci; 2000 Apr; 905():34-53. PubMed ID: 10818440
[TBL] [Abstract][Full Text] [Related]
2. Naturally occurring analogs of lysophosphatidic acid elicit different cellular responses through selective activation of multiple receptor subtypes.
Fischer DJ; Liliom K; Guo Z; Nusser N; Virág T; Murakami-Murofushi K; Kobayashi S; Erickson JR; Sun G; Miller DD; Tigyi G
Mol Pharmacol; 1998 Dec; 54(6):979-88. PubMed ID: 9855625
[TBL] [Abstract][Full Text] [Related]
3. Phospholipid growth factors and corneal wound healing.
Watsky MA; Griffith M; Wang DA; Tigyi GJ
Ann N Y Acad Sci; 2000 Apr; 905():142-58. PubMed ID: 10818450
[TBL] [Abstract][Full Text] [Related]
4. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer.
Fang X; Gaudette D; Furui T; Mao M; Estrella V; Eder A; Pustilnik T; Sasagawa T; Lapushin R; Yu S; Jaffe RB; Wiener JR; Erickson JR; Mills GB
Ann N Y Acad Sci; 2000 Apr; 905():188-208. PubMed ID: 10818454
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization.
An S; Bleu T; Zheng Y; Goetzl EJ
Mol Pharmacol; 1998 Nov; 54(5):881-8. PubMed ID: 9804623
[TBL] [Abstract][Full Text] [Related]
6. Growth factor-like phospholipids generated after corneal injury.
Liliom K; Guan Z; Tseng JL; Desiderio DM; Tigyi G; Watsky MA
Am J Physiol; 1998 Apr; 274(4):C1065-74. PubMed ID: 9575804
[TBL] [Abstract][Full Text] [Related]
7. Novel clusters of receptors for sphingosine-1-phosphate, sphingosylphosphorylcholine, and (lyso)-phosphatidic acid: new receptors for "old" ligands.
Kostenis E
J Cell Biochem; 2004 Aug; 92(5):923-36. PubMed ID: 15258916
[TBL] [Abstract][Full Text] [Related]
8. EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16.
Okamoto H; Takuwa N; Yatomi Y; Gonda K; Shigematsu H; Takuwa Y
Biochem Biophys Res Commun; 1999 Jun; 260(1):203-8. PubMed ID: 10381367
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
[TBL] [Abstract][Full Text] [Related]
10. EDG receptors and hepatic pathophysiology of LPA and S1P: EDG-ology of liver injury.
Svetlov SI; Sautin YY; Crawford JM
Biochim Biophys Acta; 2002 May; 1582(1-3):251-6. PubMed ID: 12069835
[TBL] [Abstract][Full Text] [Related]
11. Xenopus oocytes express multiple receptors for LPA-like lipid mediators.
Liliom K; Murakami-Murofushi K; Kobayashi S; Murofushi H; Tigyi G
Am J Physiol; 1996 Mar; 270(3 Pt 1):C772-7. PubMed ID: 8638656
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid receptor signaling in mammalian retinal pigment epithelial cells.
Thoreson WB; Ryan JS; Shi C; Kelly ME; Bryson EJ; Toews ML; Ediger TL; Chacko DM
Invest Ophthalmol Vis Sci; 2002 Jul; 43(7):2450-61. PubMed ID: 12091450
[TBL] [Abstract][Full Text] [Related]
13. Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction.
Rizza C; Leitinger N; Yue J; Fischer DJ; Wang DA; Shih PT; Lee H; Tigyi G; Berliner JA
Lab Invest; 1999 Oct; 79(10):1227-35. PubMed ID: 10532586
[TBL] [Abstract][Full Text] [Related]
14. The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities.
Takuwa Y; Takuwa N; Sugimoto N
J Biochem; 2002 Jun; 131(6):767-71. PubMed ID: 12038970
[TBL] [Abstract][Full Text] [Related]
15. Non-Edg family lysophosphatidic acid (LPA) receptors.
Ishii S; Noguchi K; Yanagida K
Prostaglandins Other Lipid Mediat; 2009 Sep; 89(3-4):57-65. PubMed ID: 19524700
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel growth factor-like lipid, 1-O-cis-alk-1'-enyl-2-lyso-sn-glycero-3-phosphate (alkenyl-GP) that is present in commercial sphingolipid preparations.
Liliom K; Fischer DJ; Virág T; Sun G; Miller DD; Tseng JL; Desiderio DM; Seidel MC; Erickson JR; Tigyi G
J Biol Chem; 1998 May; 273(22):13461-8. PubMed ID: 9593679
[TBL] [Abstract][Full Text] [Related]
17. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration.
Park SY; Schinkmann KA; Avraham S
Cell Signal; 2006 Jul; 18(7):1063-71. PubMed ID: 16199135
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.
Durgam GG; Tsukahara R; Makarova N; Walker MD; Fujiwara Y; Pigg KR; Baker DL; Sardar VM; Parrill AL; Tigyi G; Miller DD
Bioorg Med Chem Lett; 2006 Feb; 16(3):633-40. PubMed ID: 16263282
[TBL] [Abstract][Full Text] [Related]
19. LPA(3), a unique G protein-coupled receptor for lysophosphatidic acid.
Hama K; Aoki J
Prog Lipid Res; 2010 Oct; 49(4):335-42. PubMed ID: 20230855
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
